FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds

Advances, analyzed first-time dispensing of semaglutide and tirzepatide among more than 2 million US adults with established CVD and overweight or obesity between January 2021 and May 2025. The study ...